Publications

Found 3 results
Author [ Title(Desc)] Type Year
Filters: Author is During, Matthew J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, Ma Y, Small M, Feigin A, During MJ et al..  2018.  Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.. Sci Transl Med. 10(469)
L
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A et al..  2017.  Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.. JCI Insight. 2(7):e90133.
S
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D et al..  2007.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 369(9579):2097-105.